Abstract
Traditional antiepileptic drug development approaches have yielded many important clinically valuable anti-epileptic drugs. However, the screening of promising compounds has been naturally agnostic to epilepsy etiology in individual human patients. Now, genomic medicine is changing the way we view human disease. International collaborations are unraveling the many molecular genetic causes of the epilepsies, including the early onset epileptic encephalopathies, and some of the familial focal epilepsies. Further advances in precision diagnostics will be facilitated by ongoing large collaborations and the wider availability of whole exome and whole genome sequencing in clinical practice. Securing a precise molecular diagnosis in some individual patients will pave the way for the advent of precision therapeutics of new and re-purposed compounds in the treatment of the epilepsies. This new approach is already beginning, e.g., with the use of everolimus in patients with tuberous sclerosis complex (and perhaps other mTORopathies), the use of quinidine in some children with KCNT1 mutations, and the use of the ketogenic diet in individuals with GLUT-1 deficiency. This article explores the promise of genomics guided drug development as an approach to complement the more traditional model.
Similar content being viewed by others
Change history
21 September 2017
An erratum to this article has been published.
References
Epi4K Consortium (2012) Epi4K: Gene discovery in 4000 genomes. Epilepsia 53:1457–1467
EpiPM Consortium (2015) A road map for precision medicine in the epilepsies. Lancet Neurol 14:1219–1228
Reif PS, Tsai M-H, Helbig I et al (2016) Precision medicine in genetic epilepsies: break of dawn? Exp Rev. Neurother 17:381–392
Striano P, Vari MS, Mazzocchetti C et al (2016) Management of genetic epilepsies: from empirical treatment to precision medicine. Pharm Res 107:426–429
International League Against Epilepsy Consortium on Complex Epilepsies (2014) Genetic determinants of common epilepsies: a meta-analysis of genome-wide association studies. Lancet Neurology 13(9):893–903
McCormack M, Alfirevic A, Bourgeois S et al (2011) HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. New Engl J Med 364(12):1134–1143
Chen P, Lin J-J, Lu C-S et al (2011) Carbamazepine-induced toxic effects and HLA B*1502 screening in Taiwan. New Engl J Med 364:1126–1133
Epi4k Consortium (2013) Epilepsy Phenome/Genome Project. De novo mutations in epileptic encephalopthies. Nature 501:217–221
EuroEPINOMICS-RES Consortium, Epilepsy Phenome/Genome P, Epi4K Consortium (2014) De novo mutations in synaptic transmission genes including DNM1 cause epileptic encephalopathies. Am J Hum Genet 95:360–370
Epi4k Consortium (2016) De Novo mutations in SLC1A2 and CACNA1A are important causes of epileptic encephalopathies. Am J Hum Genet 99:287–298
Epi4k Consortium (2017) Epilepsy Phenome/Genome Project. Ultra-rare genetic variation in common epilepsies: a case-control sequencing study. Lancet Neurol 16:135–143
Dhindsa R, Goldstein DB (2015) Genetic discoveries drive molecular analyses and targeted therapeutic options in the epilepsies. Curr Neurol Neurosci Rep 15:70
Crino PB (2016) The mTOR signaling cascade: paving new roads to cure neurological disease. Nat Rev Neurol 12:379–392
Caban C, Khan N, Hasbani DM, Crino PB (2017) Genetics of tuberous sclerosis complex: implications for clinical practice. Appl Clin Genet 10:1–8
Curatolo P, Bombardieri R, Joswiak S (2008) Tuberous sclerosis. Lancet 372:657–668
Han JM, Sahin M (2011) TSC1/TSC2 signalling in the CNS. FEBS Lett 585:973–980
Citraro R et al (2016) mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis. Pharmacol Res 107:333–343
French JA, Lawson JA, Yapici Z et al (2016) Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase three, randomized, double-blind, placebo controlled study. Lancet 388:2153–2163
Ricos MG, Hodgson BL, Pippucci T et al (2016) Mutations in the mammalian target of rapamycin pathway regulators NPRL2 and NPRL3 cause focal epilepsy. Ann Neurol 79:120–131
Weckhuysen S, Marson E, Lambrecq V et al (2016) Involvement of GATOR complex genes in familial focal epilepsies and focal cortical dysplasia. Epilepsia 57:994–1003
Baldassari S, Licchetta L, Truper P et al (2016) GATOR1 complex: the common genetic actor in focal epilepsies. J Med Genet 53:503–510
Milligan CJ, Li M, Gazina Ev et al (2014) KCNT1 gain of function in two epilepsy phenotypes is reversed by quinidine. Ann Neurol 75:581–590
Beardon D, Strong A, Ehnot J et al (2014) Targeted treatment of migrating partial seizures of infancy with quinidine. Ann Neurol 76:457–461
Mikati MA, Jiang Y, Carboni M et al (2015) Quinidine in the treatment of KCNT1-positive epilepsies. Ann Neurol 78:995–999
Chong PF, Nakamura R, Saitsu H et al (2016) Ineffective quinidine therapy in early onset epileptic encephalopathy with KCNT1 mutation. Ann Neurol 79:502–503
Baraban SC, Dinday MT, Hortopan GA (2013) Drug screening in SCN1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment. Nat Commun 4:2410
Griffen A, Hamling KR, Knupp K et al (2017) Clemizole and modulators of serotonin signaling suppress seizures in Dravet syndrome. Brain. doi:10.1093/brain/aww342
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article is available at https://doi.org/10.1007/s11064-017-2396-4.
Rights and permissions
About this article
Cite this article
Delanty, N., Cavallleri, G. Genomics-Guided Precise Anti-Epileptic Drug Development. Neurochem Res 42, 2084–2088 (2017). https://doi.org/10.1007/s11064-017-2312-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11064-017-2312-y